Literature DB >> 18097298

Outcomes of a Hepatitis C screening program at a large urban VA medical center.

Holly Groom1, Eric Dieperink, David B Nelson, Judith Garrard, James R Johnson, Stephen L Ewing, Herbert Stockley, Janet Durfee, Yvonne Jonk, Mark L Willenbring, Samuel B Ho.   

Abstract

GOALS: To determine the outcomes of implementing clinical care guidelines for Hepatitis C screening, evaluation, and treatment in a large urban Veterans Affairs Medical Center.
BACKGROUND: Little information exists regarding the actual outcomes of institutional screening programs for Hepatitis C. STUDY: Retrospective review of all patients tested for Hepatitis C at the Minneapolis Veterans Affairs Medical Center from January 1, 2000 to December 31, 2001. Logistic regression was used to determine factors related to successful referral and treatment.
RESULTS: During this period 36,422 unique patients were screened for Hepatitis C virus (HCV) risk factors, resulting in 12,485 HCV enzyme-linked immunoassay antibody tests. HCV antibodies were positive in 681 (5.4%) patients and 520 (4.2%) were HCV-RNA-positive. Of HCV-RNA-positive patients, 430 (83%) were referred, 382 (73%) attended the Hepatitis clinic, and 232 (44.6%) received liver biopsies. Patients referred had significantly fewer comorbidities, known marital status, and greater prior clinic attendance than those not referred. Overall, 124 patients with established fibrosis received antiviral therapy (32% of patients attending clinic or 24% of viremic cohort). White race, fewer major medical problems, and age less than 60 years predicted antiviral treatment. Sustained virologic response occurred in 46 (37%) of treated patients (9% of the viremic cohort). Patients with a sustained virologic response include 17 patients with stage 3 to 4 fibrosis.
CONCLUSIONS: This screening and referral program resulted in 73% of HCV-RNA-positive patients attending a specialty Hepatitis C clinic and 24% of those most likely to benefit received antiviral therapy. Measures to increase referral, engagement in care, and antiviral treatment are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097298     DOI: 10.1097/MCG.0b013e31802dc56f

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  20 in total

1.  Duplicate hepatitis C antibody testing in New York City, 2006-2010.

Authors:  Victoria Tsai; Katherine Bornschlegel; Emily McGibbon; Stephen Arpadi
Journal:  Public Health Rep       Date:  2014 Nov-Dec       Impact factor: 2.792

2.  Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US.

Authors:  Ramsey Cheung; Ajitha Mannalithara; Gurkirpal Singh
Journal:  Dig Dis Sci       Date:  2010-02-26       Impact factor: 3.199

Review 3.  Estimating the true prevalence of hepatitis C in rhode island.

Authors:  Elizabeth N Kinnard; Lynn E Taylor; Omar Galárraga; Brandon D L Marshall
Journal:  R I Med J (2013)       Date:  2014-07-01

4.  Recommendations on hepatitis C screening for adults.

Authors:  Roland Grad; Brett Thombs; Marcello Tonelli; Maria Bacchus; Richard Birtwhistle; Scott Klarenbach; Harminder Singh; Veronique Dorais; Nathalie Holmes; Wendy Martin; Rachel Rodin; Alejandra Jaramillo Garcia
Journal:  CMAJ       Date:  2017-04-24       Impact factor: 8.262

Review 5.  Novel interventions to prevent HIV and HCV among persons who inject drugs.

Authors:  Phillip O Coffin; Christopher Rowe; Glenn-Milo Santos
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

Review 6.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

7.  Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Authors:  Phillip O Coffin; John D Scott; Matthew R Golden; Sean D Sullivan
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

8.  U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.

Authors:  Samuel B Ho; Bashar Aqel; Eric Dieperink; Shanglei Liu; Lori Tetrick; Yngve Falck-Ytter; Charles DeComarmond; Coleman I Smith; Daniel P McKee; William Boyd; Clark C Kulig; Edmund J Bini; Marcos C Pedrosa
Journal:  Dig Dis Sci       Date:  2011-01-11       Impact factor: 3.199

9.  Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.

Authors:  J Grebely; K Petoumenos; G V Matthews; P Haber; P Marks; A R Lloyd; J M Kaldor; G J Dore; M Hellard
Journal:  Drug Alcohol Depend       Date:  2010-03-01       Impact factor: 4.492

Review 10.  Management of rheumatic disease with comorbid HBV or HCV infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.